G C Farrell

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Nonalcoholic fatty liver disease: from steatosis to cirrhosis
    Geoffrey C Farrell
    The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
    Hepatology 43:S99-S112. 2006
  2. ncbi request reprint Management of chronic hepatitis B virus infection: a new era of disease control
    G C Farrell
    Department of Gastroenterology and Hepatology, The Canberra Hospital and Department of Medicine, Australian National University, Canberra, Australian Capital Territory, Australia
    Intern Med J 36:100-13. 2006
  3. ncbi request reprint Drug-induced hepatic injury
    G C Farrell
    Storr Liver Unit, University of Sydney at Westmead Hospital, NSW, Australia
    J Gastroenterol Hepatol 12:S242-50. 1997
  4. ncbi request reprint Clinical potential of emerging new agents in hepatitis B
    G C Farrell
    Department of Medicine, University of Sydney at Westmead Hospital, New South Wales, Australia
    Drugs 60:701-10. 2000
  5. ncbi request reprint Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Insitute, and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, New South Wales, Australia
    Gastroenterology 125:1695-704. 2003
  6. ncbi request reprint Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C
    Dinesh Kumar
    Storr Liver Unit, Westmead Millennium Institute, Westmead, New South Wales, Australia
    J Gastroenterol Hepatol 20:1395-400. 2005
  7. ncbi request reprint Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
    Claire Z Larter
    The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia
    J Hepatol 44:253-61. 2006
  8. ncbi request reprint How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Henry L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Gastroenterol Hepatol 22:801-8. 2007
  9. ncbi request reprint The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:846-54. 2007
  10. ncbi request reprint Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary
    Geoffrey C Farrell
    Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Garran, Australia
    J Gastroenterol Hepatol 22:775-7. 2007

Collaborators

Detail Information

Publications48

  1. ncbi request reprint Nonalcoholic fatty liver disease: from steatosis to cirrhosis
    Geoffrey C Farrell
    The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
    Hepatology 43:S99-S112. 2006
    ..Future challenges are to approach NAFLD as a preventive public health initiative and to motivate affected persons to adopt a healthier lifestyle...
  2. ncbi request reprint Management of chronic hepatitis B virus infection: a new era of disease control
    G C Farrell
    Department of Gastroenterology and Hepatology, The Canberra Hospital and Department of Medicine, Australian National University, Canberra, Australian Capital Territory, Australia
    Intern Med J 36:100-13. 2006
    ..Further improvements in treatment of CHB are needed to prevent drug resistance and permanently suppress viral replication by eradicating viral templates or stimulating host immune responsiveness to HBV...
  3. ncbi request reprint Drug-induced hepatic injury
    G C Farrell
    Storr Liver Unit, University of Sydney at Westmead Hospital, NSW, Australia
    J Gastroenterol Hepatol 12:S242-50. 1997
    ..Minocycline and diclofenac will be mentioned as two drugs for which drug hepatitis is an exceedingly rare complication. Finally, the evidence that Chinese herbal medicines can be hepatotoxic will be reviewed...
  4. ncbi request reprint Clinical potential of emerging new agents in hepatitis B
    G C Farrell
    Department of Medicine, University of Sydney at Westmead Hospital, New South Wales, Australia
    Drugs 60:701-10. 2000
    ....
  5. ncbi request reprint Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Insitute, and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, New South Wales, Australia
    Gastroenterology 125:1695-704. 2003
    ..Chronic hepatitis C virus infection is associated with an increased prevalence of type 2 diabetes. We hypothesized that virus-induced insulin resistance may be a mechanism for fibrogenesis in chronic hepatitis C virus infection...
  6. ncbi request reprint Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C
    Dinesh Kumar
    Storr Liver Unit, Westmead Millennium Institute, Westmead, New South Wales, Australia
    J Gastroenterol Hepatol 20:1395-400. 2005
    ..Obesity associated hepatic steatosis has been suggested to have a premalignant potential. We determined whether hepatic steatosis predisposes to liver cancer in persons with chronic hepatitis C virus (HCV) infection...
  7. ncbi request reprint Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?
    Claire Z Larter
    The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia
    J Hepatol 44:253-61. 2006
  8. ncbi request reprint How should we manage patients with non-alcoholic fatty liver disease in 2007?
    Henry L Y Chan
    Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Gastroenterol Hepatol 22:801-8. 2007
    ..Lifestyle changes are the first line and mainstay of management...
  9. ncbi request reprint The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
    Paul Angulo
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Hepatology 45:846-54. 2007
    ..By applying this model, a liver biopsy would have been avoided in 549 (75%) of the 733 patients, with correct prediction in 496 (90%)...
  10. ncbi request reprint Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary
    Geoffrey C Farrell
    Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Garran, Australia
    J Gastroenterol Hepatol 22:775-7. 2007
  11. ncbi request reprint Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines
    Shivakumar Chitturi
    Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Garran, Australia
    J Gastroenterol Hepatol 22:778-87. 2007
    ..The present document reviews the reasoning and evidence behind the APWP-NAFLD proposals for definition, assessment, and management of NAFLD in the Asia-Pacific region...
  12. ncbi request reprint Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines
    Ian Homer Y Cua
    Storr Liver Unit, Westmead Millennium Institute and Department of Gastroenterology and Hepatology, University of Sydney at Westmead Hospital, Westmead, New South Wales, Australia
    Hepatology 46:66-73. 2007
    ..HCV-associated IR is most likely an adipocytokine-independent effect of the virus to modulate insulin sensitivity...
  13. ncbi request reprint Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Institute, and Department of Gastroenterology and Hepatology, Westmead Hospital, University of Sydney, NSW, Australia
    Hepatology 38:420-7. 2003
    ..In conclusion, liver failure is the main cause of morbidity and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe than HCV-cirrhosis, except that HCC appears less common...
  14. ncbi request reprint Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression
    Shirley A Coverdale
    The Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, NSW, Australia
    Am J Gastroenterol 98:1384-90. 2003
    ..We tested whether fibrotic progression in chronic hepatitis C could be predicted by liver tests, antipyrine clearance, or platelet count...
  15. ncbi request reprint Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response
    Dinesh Kumar
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Australia
    Hepatology 36:1266-72. 2002
    ..7-481, P =.007). In conclusion, these data provide strong support for a direct causal association between HCV genotype 3 infection and hepatic steatosis...
  16. ncbi request reprint HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity
    Shivakumar Chitturi
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, New South Wales 2145, Australia
    Hepatology 36:142-9. 2002
    ..In conclusion, hepatic iron is not a factor linked to hepatic fibrogenesis in patients with NASH. HFE mutations do not confer an additional risk of hepatic fibrosis in this disorder...
  17. ncbi request reprint Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice
    Emilia Ip
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Australia
    Hepatology 38:123-32. 2003
    ....
  18. ncbi request reprint COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator
    Jun Yu
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, Australia
    Hepatology 43:826-36. 2006
    ..COX-2 may therefore be a pro-inflammatory mediator in metabolic forms of steatohepatitis...
  19. ncbi request reprint NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis
    Aileen Dela Pena
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW, Australia
    J Hepatol 46:304-13. 2007
    ..g., gp91phox) renders NADPH oxidase inactive. We tested whether activated inflammatory cells contribute to oxidant stress in steatohepatitis...
  20. ncbi request reprint Drugs and steatohepatitis
    Geoffrey C Farrell
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
    Semin Liver Dis 22:185-94. 2002
    ..It follows that early recognition of hepatotoxicity is crucial to prevent the development of severer forms of liver disease and improve the clinical outcome...
  21. ncbi request reprint New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection
    Geoffrey C Farrell
    J Gastroenterol Hepatol 22:607-10. 2007
  22. ncbi request reprint TNF-alpha as therapeutic target in NASH: tried, but not yet proven
    Shivakumar Chitturi
    J Gastroenterol Hepatol 22:613-4. 2007
  23. ncbi request reprint Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, New South Wales, Australia
    Am J Gastroenterol 97:1003-9. 2002
    ..The aim of the present study was to assess the effect of lamivudine therapy on hepatic synthetic function in patients with moderately severe chronic hepatitis B and, particularly, to determine the effect of drug resistance...
  24. ncbi request reprint Liver regeneration in obese mice with fatty livers: does the impairment have relevance for other types of fatty liver disease?
    Geoffrey C Farrell
    Hepatology 35:731-2. 2002
  25. ncbi request reprint Lipoprotein lipase activator ameliorates the severity of dietary steatohepatitis
    Jun Yu
    Institute of Digestive Disease, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
    Biochem Biophys Res Commun 356:53-9. 2007
    ..These findings indicate that NO-1886 is a potential therapeutic agent for steatohepatitis...
  26. ncbi request reprint NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
    Shivakumar Chitturi
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, New South Wales, Australia
    Hepatology 35:373-9. 2002
    ..IR is present in mild as well as advanced cases of NASH but is unusual in chronic HCV of similar fibrotic severity...
  27. ncbi request reprint Fatty liver now, diabetes and heart attack later? The liver as a barometer of metabolic health
    Shivakumar Chitturi
    J Gastroenterol Hepatol 22:967-9. 2007
  28. ncbi request reprint Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation
    Claire Z Larter
    Australian National University Medical School at The Canberra Hospital, Canberra, Australian Capital Territory, Australia
    J Gastroenterol Hepatol 23:267-75. 2008
    ..n-3 polyunsaturated fatty acids (PUFA), such as those found in fish oil (FO), are naturally occurring PPARalpha ligands which also suppress lipid synthesis...
  29. doi request reprint Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways
    Claire Z Larter
    Department of Gastroenterology and Hepatology, ANU Medical School, Australian National University at The Canberra Hospital, ACT, Australia
    J Hepatol 48:638-47. 2008
    ..We determined the effects of dietary lipid composition on steatohepatitis development with particular attention to the nature of lipid molecules that accumulate in the liver and pathways of hepatic triglyceride synthesis...
  30. doi request reprint Hepatotoxic slimming aids and other herbal hepatotoxins
    Shivakumar Chitturi
    Gastroenterology and Hepatology Unit, The Canberra Hospital, Canberra, Australian Capital Territory, Australia
    J Gastroenterol Hepatol 23:366-73. 2008
    ....
  31. ncbi request reprint Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice
    Todor Arsov
    John Curtin School of Medical Research, The Australian National University ANU, Canberra, ACT, Australia
    Biochem Biophys Res Commun 342:1152-9. 2006
    ..In this model of metabolic syndrome, transition of steatosis to steatohepatitis was associated with hypoadiponectinemia, a mediator of hepatic fatty acid disposal pathways...
  32. ncbi request reprint Leptin is essential for the hepatic fibrogenic response to chronic liver injury
    Isabelle A Leclercq
    Storr Liver Unit, Department of Medicine and Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW 2145, Australia
    J Hepatol 37:206-13. 2002
    ..The correlation between increased leptin, obesity and hepatic fibrosis prompted us to hypothesise that leptin has profibrogenic effects on the liver...
  33. ncbi request reprint Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice
    Robert S McCuskey
    Department of Cell Biology and Anatomy, College of Medicine, University of Arizona, Tucson, AZ 85724 5044, USA
    Hepatology 40:386-93. 2004
    ..In conclusion, these results are consistent with a dysfunctional hepatic microvasculature. Thus, microvascular changes may contribute to progressive liver injury in metabolic and toxic forms of steatohepatitis...
  34. ncbi request reprint Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury
    Isabelle A Leclercq
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, NSW, Australia
    Gastroenterology 124:1451-64. 2003
    ..Our aim was to establish whether defective liver regeneration in ob/ob mice is a direct consequence of leptin-dependent, intracellular signaling mechanisms controlling cell-cycle regulation in hepatocytes...
  35. ncbi request reprint Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them
    Jason M Hui
    J Gastroenterol Hepatol 18:1115-7. 2003
  36. ncbi request reprint Pharmacotherapy of hepatocellular carcinoma
    John F Perry
    AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Rd, Camperdown 2050, Australia
    Expert Opin Pharmacother 4:2175-85. 2003
    ..This review summarises some of the therapeutic modalities used for HCC, with an emphasis on pharmacological therapies...
  37. ncbi request reprint Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting
    Dinesh Kumar
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
    Med J Aust 178:267-71. 2003
    ....
  38. ncbi request reprint Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?
    Shivakumar Chitturi
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia
    J Gastroenterol Hepatol 19:368-74. 2004
    ..Pharmacotherapy may play a role in selected individuals. A regional agenda for case definition, future study and public health initiatives is urgently required...
  39. ncbi request reprint Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study
    Shirley A Coverdale
    Storr Liver Unit, Westmead Millennium Institute and University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia
    Am J Gastroenterol 99:636-44. 2004
    ..After accounting for these factors, we tested whether interferon treatment or the treatment response reduces the rate of liver cancer, liver-related death or transplantation, and other liver complications during extended follow-up...
  40. ncbi request reprint Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index
    Archana Sud
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead, New South Wales, Australia
    Hepatology 39:1239-47. 2004
    ..Such an index should prove useful to guide decision making regarding the need for liver biopsy, and potentially for avoiding or deferring biopsy in a large proportion of patients with mild liver disease...
  41. ncbi request reprint High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD
    Jason M Hui
    Hepatology 39:1458-9. 2004
  42. ncbi request reprint Beyond insulin resistance in NASH: TNF-alpha or adiponectin?
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, and Department of Gastroenterology and Hepatology, Westmead Hospital, NSW, Australia
    Hepatology 40:46-54. 2004
    ..Reduced adiponectin level is associated with more extensive necroinflammation and may contribute to the development of necroinflammatory forms of NAFLD...
  43. ncbi request reprint Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?
    Geoffrey C Farrell
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney at Westmead Hospital, New South Wales, Australia
    J Gastroenterol Hepatol 18:124-38. 2003
    ..Some emerging concepts on pathogenesis will be mentioned briefly, but the emphasis will be on the potency of lifestyle adjustments (physical activity and diet) to prevent or reverse fatty liver disorders...
  44. ncbi request reprint Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice
    Isabelle A Leclercq
    Gastroenterology Unit, Universite Catholique de Louvain UCL, GAEN UCL 53 79, avenue E Mounier, 53, B 1200 Brussels, Belgium
    J Hepatol 41:926-34. 2004
    ..We analysed the role of NF-kappaB redox-sensitive signalling pathway of inflammatory recruitment in experimental steatohepatitis...
  45. ncbi request reprint Antioxidant levels in peripheral blood, disease activity and fibrotic stage in chronic hepatitis C
    Priyanka Bandara
    Storr Liver Unit, Westmead Millennium Institute, Sydney, Australia
    Liver Int 25:518-26. 2005
    ..We then determined whether regular antioxidant supplementation influenced these antioxidant levels or disease severity...
  46. ncbi request reprint Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection
    Jason M Hui
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Department of Anatomical Pathology, New South Wales, Australia
    J Gastroenterol Hepatol 17:873-81. 2002
    ..In the present prospective study, we examined metabolic factors associated with non-alcoholic fatty liver and viral genotype as predictors of steatosis and fibrosis in chronic hepatitis C infection...
  47. ncbi request reprint Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo
    Jun Yu
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney, Westmead Hospital, Westmead, NSW 2145, Australia
    Hepatology 43:134-43. 2006
    ..PPARgamma therefore represents a putative molecular target for chemopreventive therapy or inhibition of liver cancer growth...
  48. doi request reprint VAT fat is bad for the liver, SAT fat is not!
    Jian Gao Fan
    J Gastroenterol Hepatol 23:829-32. 2008